FLOWHIJACKED
Askעברית
Menu

FLOW HIJACKED · PSYCHOPHARMACOLOGY ATLAS · V0.1

The drug is not a dot. It is a changing intervention inside a living system.

From molecule and target to circuit, body, experience, environment and adaptation—then back to the same medicine after the system itself has changed.

Enter the Atlas See how evidence is governed
136CANONICAL DRUG RECORDS
200PUBLICATIONS ACQUIRED
3 · 12 · 11TIME SERIES · CLAIM PROFILES · FRONTIER
01 · Mmolecule
02 · Ttarget
03 · Nneuron
04 · Ccircuit
05 · Wnetwork
06 · Bbody
07 · Eexperience
08 · Aaction
09 · Xenvironment
10 · Ffeedback
11 · τadaptation
12 · M′changed response
the system returning to the molecule has changed
REGULATORY TRUTH VERIFIED THROUGH AUGUST 2026 · JURISDICTION-SPECIFICONE VERIFIED OBJECT · MANY NAVIGATION DOORS · NO FACT FORKING

00 · BEFORE THE FIRST DRUG

Not every line in the Atlas knows equally well.

The Atlas separates in-vitro binding, therapeutic human exposure, target engagement, circuit association, plausible network consequence and demonstrated clinical outcome. That separation is not a footnote. It is the architecture.

01

Canonical object, intentional duplication

One drug record is verified once and then appears through disorder, pathway, burden and trajectory doors without forking its facts.

02

Regulatory truth has a date and place

Every status carries a jurisdiction boundary and 'verified through August 2026'.

03

Affinity is not exposure

In-vitro binding, therapeutic exposure, human occupancy and demonstrated relevance never share one visual weight.

04

Magnitude, time, comparator

Adverse effects show absolute incidence or effect size when available, plus comparator, dose/time pattern, reversibility and uncertainty.

Inclusion rule

Licensed psychiatric medicines worldwide; major evidence-supported off-label uses; historically important agents; addiction pharmacotherapies; and serious investigational compounds with human clinical evidence.

Laboratory-only molecules and compounds without meaningful human clinical evidence remain outside the Master Clinical Atlas and, if useful, appear only in Frontier.

01 · ATLAS WORKSPACE

One medicine. Many doors. One versioned truth.

Search by medicine, disorder, pathway or adverse burden. Duplication exists in navigation only; every result returns to the same canonical record.

136MATCHING RECORDSPAGE 1 / 12
NO ENDLESS SCROLL · 12 AT A TIME
LicensedVERIFIED TIME SERIES · 5 MOMENTS

Olanzapine

אולנזפין · Second-generation antipsychotic

A clinically effective antipsychotic whose early calming and sleep effects can arrive before its full therapeutic evaluation—and whose metabolic burden can begin on the same timeline.

HALF-LIFE21–54 h; mean ~30 h

Half-life is not clinical duration and never a self-taper schedule.

REGULATORY TRUTHAugust 2026

Licensed status and exact indications vary by jurisdiction and formulation

INDICATION DOORS
schizophreniamaniabipolar maintenancebipolar depression with fluoxetine
PATHWAYS
mesolimbic dopaminemesocortical dopamineserotonin
BURDENS TO FOLLOW
metabolicsedationakathisiaprolactin
FAVOURABLE CLINICAL USE

Acute schizophrenia and psychosis · Acute mania and bipolar maintenance · Agitation and sleep may improve early for some people

Open the depth profile ↓

02 · TRAJECTORY VIEW

Psychopharmacology happens in time. The static card hides the story.

SELECTED TRAJECTORY

Olanzapine

A clinically effective antipsychotic whose early calming and sleep effects can arrive before its full therapeutic evaluation—and whose metabolic burden can begin on the same timeline.

First hoursτ01
EXPOSURE

Peak concentration is reached over hours; sedation, orthostasis or calming can appear before antipsychotic outcome can be judged.

BODY & EXPERIENCE

Sleepiness, dry mouth, dizziness or increased appetite may be noticeable.

ADAPTATION

One dose is exposure, not a verdict about long-term fit.

WHAT THE EVIDENCE KNOWS

Label pharmacokinetics and short-term trials; high confidence for exposure, lower for individual experience.

Trajectory View is an evidence-and-adaptation map, not a personal forecast or discontinuation schedule.

03 · THE EPISTEMIC FIREWALL

A coherent mechanism is not yet a demonstrated causal chain.

high

Known molecular action

Antagonism across dopamine D₂, serotonin 5-HT₂A and several histamine, muscarinic and serotonergic targets.

CONFIDENCE APPLIES TO THIS CLAIM LEVEL ONLY

AFFINITY ≠ EXPOSURE ≠ OCCUPANCY ≠ RELEVANCE

Not every receptor on a binding sheet belongs in the clinical story equally.

The same H1, muscarinic and serotonergic profile that may help sleep, agitation or nausea can also increase sedation, appetite and metabolic burden. Benefit and burden do not occupy separate molecules.

TARGETAFFINITYEXPOSUREOCCUPANCYRELEVANCE
D₂

High in vitro affinity

Therapeutic concentrations reach a clinically relevant range

Human PET supports substantial striatal occupancy; dose and person matter

Strong link to antipsychotic effect and some motor/endocrine burden

5-HT₂A

High in vitro affinity

Likely engaged at usual exposure

Human imaging supports engagement

Contributes to the drug’s clinical profile; not a stand-alone explanation

H₁ / 5-HT₂C / M₁

Meaningful in vitro binding

Likely clinically relevant

Target-specific human occupancy is less complete than the D₂ story

Plausibly contributes to sedation, appetite, weight and anticholinergic effects

BEYOND 'CAN CAUSE'

Magnitude, comparator, time, reversibility and uncertainty.

high

≥7% body-weight gain

22.2% in pooled short-term adult trials
Comparator
3% with placebo
Time
Median time to event: 8 weeks
Reversibility
Variable; may persist without active management
FDA olanzapine prescribing information
high

Somnolence

26% in premarketing adult data
Comparator
15% with placebo
Time
Often early; dose related
Reversibility
May attenuate; individual course varies
DailyMed / FDA labelling
moderate

Long-term mean weight change

+5.6 kg in studies ≥48 weeks
Comparator
Uncontrolled long-term pool
Time
Median exposure 573 days
Reversibility
Not established by this estimate
FDA olanzapine prescribing information

04 · CONTRADICTION ROOM

An Atlas that ages honestly must preserve what has not been settled.

Contradiction, heterogeneity, inference gap and clinical trade-off are not the same. Each cluster receives a versioned state instead of prose that dissolves the disagreement.

resolved-distinction

SSRIs work ≠ depression is a serotonin deficiency

Proximal drug action, disease cause and clinical outcome are different claims. Evidence for one does not automatically establish the others.

CONTRADICTION STATE IS RE-REVIEWED WITH EACH LEDGER VERSION
PALMER · BRAIN ENERGY

A hypothesis generator, never an epistemic shortcut.

The question is not whether all psychiatric illness is mitochondrial, but where energetic variables measurably constrain neural dynamics or treatment response across disorders, subgroups, medicines and physiological states.

STROGATZ → IZHIKEVICH

Pedagogy, mathematics, neuron—then a disciplined stop.

The Joy of x supplies the teaching ethic; Nonlinear Dynamics and Chaos the vocabulary; Izhikevich the bridge to excitability. None licenses a leap from neuronal bifurcation to a person’s diagnosis.

PLAYLIST INTAKE GATE

Enumerate. Extract. Independently verify.

No playlist item, claim or quotation enters the ledger because it sounds plausible. Items are enumerated first, claims extracted second and every claim independently verified third.

05 · VERSIONED EVIDENCE LEDGER

200 publications. Not a finished bibliography—a system built to change.

Initial PubMed acquisition across 12 balanced streams, deduplication, landmark pinning and transparent prioritisation. The grade describes study design—not truth, applicability or freedom from bias.

VERIFIED THROUGHAugust 2026
DATABASEPubMed / NCBI E-utilities
ACQUISITION STREAMS12
DEFAULT CONTRADICTION STATEnot-yet-coded
200RESULTS
PAGE 1 / 25 · NO ENDLESS SCROLL
WHAT THE GRADE MEANS

Publication design: meta-analysis, systematic review, randomised trial or another design.

WHAT IT DOES NOT MEAN

That a claim is true, unbiased, applicable to every person or worth more than its burden.

NEXT LEDGER PASS

Claim coding, direction, magnitude, population, bias risk, contradiction state and superseding evidence.